PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.

$45.9M

Market Cap • 5/9/2025

2013

(12 years)

Founded

2020

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of US

Princeton

Headquarters • New Jersey